

1/13

H<sub>2</sub>N-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAI-CO<sub>2</sub>H (SEQ ID NO: 1 )  
1 10 20 30 40

FIG. 1

H<sub>2</sub>N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Cys-amide (SEQ ID NO: 2)  
1 5 10 15

FIG. 2

Cys-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-amide (SEQ ID NO: 3)  
10 15 20 25

FIG. 3

Cys-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr-CO<sub>2</sub>H (SEQ ID NO: 4)  
35 40

FIG. 4

FOOT-1652560




FIG. 5




FIG. 6




FIG. 7

T090T" 46626560




FIG. 8






FIG. 9






Transition-state



Phosphonate



Phosphoramidate

FIG. 11




FIG. 12






FIG. 13




FIG. 14

11/13

Anti-A $\beta$  Transition-state Antibodies Plus  $^{125}$ I-A $\beta$ -Sephacose





FIG. 15

12/13



Receptor-Positive Cells

FIG. 16




FIG. 17